Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

556
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
556
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

432
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
432
Accessory Structures of the Eye01:17

Accessory Structures of the Eye

1.5K
Optical perception, or vision, is an extraordinary sense dependent on converting light signals received via the ocular organs. These organs, known as eyes, are securely positioned within the bony cavities of the skull, called orbits. The orbits serve a dual purpose: a protective shield for the ocular globes and a stable attachment point for the soft ocular tissues. The eye's external protective mechanisms include the eyelids, which are edged with lashes that act as a barrier against foreign...
1.5K
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

6.0K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

480
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
480
Focusing of Light in the Eye01:16

Focusing of Light in the Eye

2.7K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eyes on New Product Development-Number 134.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same author

Use of Clinical Pharmacology in Slowing the Myopia Epidemic.

Clinical pharmacology and therapeutics·2026
Same author

Eyes on New Product Development-Number 133.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same author

Remote Tonometry Identifies Significant Variability in the Timing of Intraocular Pressure Response to Topical Medication Change.

Ophthalmology. Glaucoma·2026
Same author

Eyes on New Product Development-Number 132.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same author

Eyes on New Product Development.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026
Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.1K

Ocular Pharmacology.

Gary D Novack1,2, Alan L Robin3,4,5

  • 1PharmaLogic Development, Inc., San Rafael, CA, USA.

Journal of Clinical Pharmacology
|May 6, 2024
PubMed
Summary
This summary is machine-generated.

Treating eye diseases requires special pharmaceutical considerations for drug delivery and formulation. Understanding ocular pharmacokinetics is key for effective and safe treatments for various eye conditions.

Keywords:
glaucomamacular degenerationophthalmologypharmacology

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.4K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

797

Related Experiment Videos

Last Updated: Jun 27, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.1K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.4K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

797

Area of Science:

  • Ophthalmology
  • Clinical Pharmacology
  • Pharmaceutics

Background:

  • Ocular disease treatment presents unique challenges for clinicians and clinical pharmacologists.
  • Ophthalmic pharmaceuticals necessitate careful consideration of solubility, pH, osmolarity, sterility, and stability.
  • The eye's unique physiology, including barriers and metabolic enzymes, impacts drug delivery and efficacy.

Purpose of the Study:

  • To review the challenges and opportunities in treating ocular diseases pharmacologically.
  • To discuss the pharmacokinetic and pharmaceutic considerations for ophthalmic drugs.
  • To highlight the diverse therapeutic approaches for ocular conditions.

Main Methods:

  • Review of ophthalmic pharmaceutical properties and delivery routes.
  • Analysis of ocular pharmacokinetics and physiological barriers.
  • Discussion of therapeutic strategies for ocular diseases.

Main Results:

  • Ophthalmic drug formulation requires attention to physical and chemical properties for optimal delivery.
  • Ocular pharmacokinetics are complex due to the eye's closed nature and specific barriers.
  • Effective treatment strategies involve topical, intravitreal, and systemic delivery methods, alongside patient adherence.

Conclusions:

  • Optimizing pharmaceutics and understanding ocular pharmacokinetics are crucial for effective ocular disease management.
  • Addressing adherence and instillation techniques is vital for patient outcomes.
  • Pharmacological treatments for ocular diseases range from those similar to systemic conditions to those unique to the eye.